Ticker: VNRX

VolitionRx Limited (VNRX) - NYSE American Quick summary This is an Amendment No. 1 to VolitionRx's Form 10‑Q for the quarter ended June 30, 2025 (originally filed Aug 14, 2025). The amendment was filed to add omitted exhibits (not to change financial results). It does not include or revise the co...

VolitionRx Limited (NYSE: VNRX) Quick take - what's happening inside VolitionRx is shrinking R&D and clinical spend, raising cash through debt and equity, and pushing commercialization of its Nu.Q® product family (notably Nu.Q® Vet). Results show modest revenue growth but large recurring losses, ...

Company Overview: VolitionRx Limited (NYSE: VNRX) is focused on developing innovative blood tests for disease diagnostics, including cancer and conditions linked to NETosis, such as sepsis. The company aims to enhance healthcare through its technologies, such as the Nu.Q® series of tests. Recent ...